Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating ELV001 as an add-on therapy for adults with active rheumatoid arthritis who have not responded adequately to methotrexate and tumor necrosis factor inhibitors. This Phase 2 randomized, double-blind, placebo-controlled study aims to assess the safety and effectiveness of different doses of ELV001. Approximately 180 to 220 participants aged 18 to 75 years will be enrolled. Participants will be assigned to one of four groups placebo, ELV001 25 mg, 75 mg, or 125 mg daily. The study includes a 4-week screening period, a 12-week double-blind placebo-controlled treatment phase, followed by a 12-week extension where some participants receive higher doses of ELV001. A 4-week safety follow-up concludes the 32-week study. During the study, participants will undergo regular assessments including disease activity scoring, joint counts, blood tests, vital signs, electrocardiograms, and questionnaires about health and function. Researchers will monitor adverse events and drug levels in the blood. The main outcome measured is the change in disease activity score from baseline to week 12. Safety and efficacy will be tracked through week 28, with total participation lasting up to 32 weeks.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes obinutuzumab in adolescents aged 12 to less than 18 years with active Class III or IV lupus nephritis confirmed by biopsy. This phase II randomized, double-blind, placebo-controlled study also monitors the safety and pharmacokinetics of obinutuzumab in younger children aged 5 to less than 12 years with lupus nephritis. Participants aged 12 to less than 18 will be randomly assigned to receive either obinutuzumab or a placebo through intravenous infusions on Day 1, Day 14, Week 24, Week 26, and Week 52. Those weighing 45 kg or more will receive a 1000 mg dose, while those under 45 kg will receive a weight-adjusted dose. Younger participants aged 5 to less than 12 will receive open-label obinutuzumab infusions on the same schedule. All participants will also take mycophenolate mofetil orally and corticosteroids such as prednisone with dose adjustments over time. Pre-medications including acetaminophen, diphenhydramine, and methylprednisolone are given before infusions. Throughout the study, participants will undergo regular assessments including laboratory tests, kidney function evaluations, disease activity scores, and quality of life measurements up to Week 76. Researchers will monitor kidney response, adverse events, drug levels, immune responses, and other health indicators. Participants will have scheduled visits aligned with the infusion days and follow-up evaluations to track treatment effects and safety over the course of the trial, which lasts until Week 76 after the first dose.
Actively Recruiting
Pain relief in children can be difficult in places with limited medical resources due to lack of medicine, equipment, or trained staff. This research aims to test a simple and low-cost method to reduce pain using a kaleidoscope as a distraction during dressing changes for children with partial thickness burns. The study will compare pain levels between children receiving usual care and those who also use the kaleidoscope to see if this method helps reduce pain during these procedures. The trial will randomly assign children aged 7 to 12 with partial thickness burns covering no more than 10% of their body to one of two groups. One group will receive standard care, which may include no pain medication or use of paracetamol or NSAIDs during dressing changes. The other group will receive the same care plus distraction by looking through a kaleidoscope during the dressing change, starting when the procedure begins and continuing until a minute after it ends. Participants will be monitored for changes in pain before, during, and after dressing changes using pain scores. Heart rate and oxygen levels will also be measured at multiple points. Researchers will also assess satisfaction and procedure duration. The study expects to show that this distraction technique is feasible and helpful for pain relief in low-resource environments, potentially improving psychological well-being and recovery in children undergoing painful treatments.
Actively Recruiting
Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.
Actively Recruiting
Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.